Literature DB >> 27324921

Exclusion criteria in treatment research on alcohol, tobacco and illicit drug use disorders: A review and critical analysis.

Christine A Moberg1,2, Keith Humphreys1,2.   

Abstract

ISSUES: High rates of exclusion in substance use disorder treatment studies reduce the external validity and clinical utility of research findings to an unknown extent. Accordingly, the current review examined commonly used exclusion criteria and their effect on study samples and outcomes. APPROACH: English-language literature was identified by PubMed searches and review of identified articles' reference lists. Studies were included if they analysed data on: (i) the prevalence and nature of exclusion criteria in the substance use disorder treatment field; and/or (ii) the impact of exclusion criteria on sample representativeness or study results. KEY
FINDINGS: The search yielded 22 studies examining different aspects of exclusion criteria, including 15 empirical examinations of the impact of study exclusion criteria across different substance use disorder treatments on enrolment and outcome results. Aggregating across these 15 studies, we estimated that between 64 and 96% of potential study participants are excluded from substance use disorder treatment studies. IMPLICATIONS: The widespread exclusion of large proportions of people with substance use disorders limits the external validity of the substance use disorder treatment research literature.
CONCLUSION: Although some eligibility criteria are necessary to protect participant safety and ensure internal validity, researchers conducting studies on substance use disorder treatments should thoughtfully consider the justification for and specific operationalisation of the extensive exclusion criteria they often utilise. [Moberg C, Humphreys K. Exclusion criteria in treatment research on alcohol, tobacco and illicit drug use disorders: A review and critical analysis. Drug Alcohol Rev 2017;36:378-388].
© 2016 Australasian Professional Society on Alcohol and other Drugs.

Entities:  

Keywords:  eligibility; exclusion criterion; external validity; generalisability; substance use

Mesh:

Year:  2016        PMID: 27324921     DOI: 10.1111/dar.12438

Source DB:  PubMed          Journal:  Drug Alcohol Rev        ISSN: 0959-5236


  6 in total

1.  Generalizability of findings from randomized controlled trials: application to the National Institute of Drug Abuse Clinical Trials Network.

Authors:  Ryoko Susukida; Rosa M Crum; Cyrus Ebnesajjad; Elizabeth A Stuart; Ramin Mojtabai
Journal:  Addiction       Date:  2017-03-16       Impact factor: 6.526

Review 2.  Extended-release injectable naltrexone for opioid use disorder: a systematic review.

Authors:  Brantley P Jarvis; August F Holtyn; Shrinidhi Subramaniam; D Andrew Tompkins; Emmanuel A Oga; George E Bigelow; Kenneth Silverman
Journal:  Addiction       Date:  2018-03-24       Impact factor: 6.526

3.  Comparing pharmacological treatments for cocaine dependence: Incorporation of methods for enhancing generalizability in meta-analytic studies.

Authors:  Ryoko Susukida; Rosa M Crum; Hwanhee Hong; Elizabeth A Stuart; Ramin Mojtabai
Journal:  Int J Methods Psychiatr Res       Date:  2018-02-21       Impact factor: 4.182

4.  Inclusion of Cannabis Users in Alcohol Research Samples: Screening In, Screening Out, and Implications.

Authors:  Alexandra Venegas; Lindsay R Meredith; Ziva D Cooper; Brandon Towns; Lara A Ray
Journal:  Alcohol Alcohol       Date:  2020-06-25       Impact factor: 3.913

5.  Association between Biomarkers of Oxidative Stress and Inflammation with Cardiac Necrosis and Heart Failure in Non-ST Segment Elevation Myocardial Infarction Patients and Various Degrees of Kidney Function.

Authors:  Stefanos Roumeliotis; Andrej Veljkovic; Panagiotis I Georgianos; Gordana Lazarevic; Zoran Perisic; Jovan Hadzi-Djokic; Vassilios Liakopoulos; Gordana Kocic
Journal:  Oxid Med Cell Longev       Date:  2021-11-01       Impact factor: 6.543

Review 6.  Exclusion criteria and generalizability in bipolar disorder treatment trials.

Authors:  Jessie J Wong; Nev Jones; Christine Timko; Keith Humphreys
Journal:  Contemp Clin Trials Commun       Date:  2018-01-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.